The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has implemented a cap on trade margins for 137 anti-cancer drugs based on recommendations from an Expert Committee constituted by the Directorate General of Health Services on 17th October 2026. The revised Maximum Retail Prices (MRPs) for these medicines came into effect on 9th November 2026. As of 8th November 2026, 85 pharmaceutical companies have reported revised MRPs for 1,364 anti-cancer formulations covering 121 drugs, with 679 brands implementing price reductions of more than 50%. The highest reported reduction in MRP reached 96.45%. This regulatory action is projected to generate annual consumer savings of ₹3,540.38 crore. Consumers can verify the revised MRPs printed on medicine packs through the Pharma Sahi Daam mobile application or the NPPA website (nppa.gov.in). The regulation prohibits chemists and hospital pharmacies from charging above the revised MRP, with grievances regarding overcharging or pricing issues to be registered through the Pharma Jan Samadhan portal or the NPPA helpline at 1800-111-255.